UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 19, 2019

 

Vaxart, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-35285

 

59-1212264

(State or other jurisdiction of
incorporation)

 

(Commission File No.)

 

(I.R.S. Employer Identification No.)

 

290 Utah Ave.

Suite 200

South San Francisco, California 94080

(Address of principal executive office)(zip code)

 

Registrant’s telephone number, including area code: (650) 550-3500

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 


 

Item 8.01                                            Other Events.

 

On March 19, 2019, Vaxart, Inc. (the “Company”) issued a press release announcing the initiation of a Phase 1b bivalent norovirus vaccine clinical trial. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

 

2


 

Item 9.01                                            Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit

 

Description

 

 

 

99.1

 

Press release, dated March 19, 2019, titled “Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial”.

 

3


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Vaxart, Inc.

 

 

Date: March 19, 2019

By:

/S/ WOUTER W. LATOUR, M.D.

 

 

Name:

Wouter W. Latour, M.D.

 

 

Title:

President and Chief Executive Officer

 

4


Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Vaxart Charts.
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Vaxart Charts.